Abstract:High-throughput screening (HTS) has achieved a dominant role in drug discovery over the past 2 decades. The goal of HTS is to identify active compounds (hits) by screening large numbers of diverse chemical compounds against selected targets and/or cellular phenotypes. The HTS process consists of multiple automated steps involving compound handling, liquid transfers, and assay signal capture, all of which unavoidably contribute to systematic variation in the screening data. The challenge is to distinguish biologically active compounds from assay variability. Traditional plate controls-based and non-controls-based statistical methods have been widely used for HTS data processing and active identification by both the pharmaceutical industry and academic sectors. More recently, improved robust statistical methods have been introduced, reducing the impact of systematic row/column effects in HTS data. To apply such robust methods effectively and properly, we need to understand their necessity and functionality. Data from 6 HTS case histories are presented to illustrate that robust statistical methods may sometimes be misleading and can result in more, rather than less, false positives or false negatives. In practice, no single method is the best hit detection method for every HTS data set. However, to aid the selection of the most appropriate HTS data-processing and active identification methods, the authors developed a 3-step statistical decision methodology. Step 1 is to determine the most appropriate HTS data-processing method and establish criteria for quality control review and active identification from 3-day assay signal window and DMSO validation tests. Step 2 is to perform a multilevel statistical and graphical review of the screening data to exclude data that fall outside the quality control criteria. Step 3 is to apply the established active criterion to the quality-assured data to identify the active compounds.

A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays

Issues of Z-factor and an approach to avoid them for quality control in high-throughput screening studies

EBT: a Statistic Test Identifying Moderate Size of Significant Features with Balanced Power and Precision for Genome-Wide Rate Comparisons

Completing the Screen: Biochemical Cascades to Prioritize HTS Output

Identifying Actives from HTS Data Sets: Practical Approaches for the Selection of an Appropriate HTS Data-Processing Method and Quality Control Review

Using Microscale Thermophoresis to Characterize Hits from High-Throughput Screening: A European Lead Factory Perspective

Compartmentalization of Enhanced Biomolecular Interactions for High-Throughput Drug Screening in Test Tubes

High-throughput screening normalized to biological response: application to antiviral drug discovery

Optimal design for high-throughput screening via false discovery rate control

Bayesian Multi Plate High Throughput Screening of Compounds

High Throughput Screening of Chromatographic Phases for Rapid Process Development

High Throughput, Label-free Screening Small Molecule Compound Libraries for Protein-Ligands Using Combination of Small Molecule Microarrays and a Special Ellipsometry-based Optical Scanner.

High-throughput mechanistic screening of non-equilibrium inhibitors by a fully automated data analysis pipeline in early drug-discovery

Hit screening with multivariate robust outlier detection

[The role and application of high-throughput screening in the search for chemical compounds of therapeutic activity]

Development and Application of Activity-based Fluorescent Probes for High-Throughput Screening

New developments and emerging trends in high-throughput screening methods for lead compound identification

Toward a Benchmarking Data Set Able to Evaluate Ligand- and Structure-based Virtual Screening Using Public HTS Data.

High-Throughput Screening Assay Profiling for Large Chemical Databases

High throughput screening of physicochemical properties and in vitro ADME profiling in drug discovery

ChemFH: an integrated tool for screening frequent false positives in chemical biology and drug discovery